Search - tctmd.com

Displaying 181 - 200 of 695

Sort: Relevancy | Date

REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status

News Conference News HFSA 2022

REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status

October 07, 2022

GDMT With ARNI Lessens MR, Perhaps Obviating Need for Interventions

News Conference News HFSA 2022

GDMT With ARNI Linked to Less MR, May Obviate Need for Interventions

Michael O'Riordan

October 04, 2022

Valve Fracture for ViV TAVI Linked With Higher Mortality

News Conference News TCT 2022

Valve Fracture for ViV TAVI Linked With Higher Mortality

Michael O'Riordan

September 22, 2022

Mix of Patient, Procedural, and Device Factors All Drove TAVI Advances

News Conference News TCT 2022

Mix of Patient, Procedural, and Device Factors All Drove TAVI Advances

September 19, 2022

RADIANCE II Confirms Ultrasound-Based Renal Denervation Lowers BP

News Conference News TCT 2022

RADIANCE II Confirms Ultrasound-Based Renal Denervation Lowers BP

September 18, 2022

Sizing Mismatch a Problem for Balloon-Expandable Valves in Small Annuli TAVI

News Conference News TCT 2022

Sizing Mismatch a Problem for Balloon-Expandable Valves in Small Annuli TAVI

Yael L. Maxwell

September 18, 2022

Both Surgical, Percutaneous Closure Boost Survival in Post-STEMI VSD

News Conference News TCT 2022

Both Surgical, Percutaneous Closure Boost Survival in Post-STEMI VSD

September 18, 2022

TRILUMINATE Pivotal Trial: First Data Support Safety, Efficacy of TriClip

News Conference News TCT 2022

TRILUMINATE Pivotal Trial: First Data Support Safety, Efficacy of TriClip

September 17, 2022

TEER Linked to Better 1-Year Survival in Shock Patients With Significant MR

News Conference News TCT 2022

TEER Linked to Better 1-Year Survival in Shock Patients With Significant MR

Yael L. Maxwell

September 17, 2022

Pascal TEER Device as Good as MitraClip in Head-to-Head CLASP IID

News Conference News TCT 2022

Pascal TEER Device as Good as MitraClip in Head-to-Head CLASP IID

Michael O'Riordan

September 17, 2022

PROTECTED TAVR: No Less Stroke With Embolic Protection, but Some See Hope

News Conference News TCT 2022

PROTECTED TAVR: No Less Stroke With Embolic Protection, but Some See Hope

September 17, 2022

TAVI Sees Rapid Growth for Severe AS Across Age Spectrum in US

News Conference News TCT 2022

TAVI Sees Rapid Growth for Severe AS Across Age Spectrum in US

September 16, 2022

Routine Functional Testing Unnecessary After Stenting: POST-PCI

News Conference News ESC 2022

Routine Functional Testing Unnecessary After Stenting: POST-PCI

Yael L. Maxwell

September 06, 2022

Smartphone App Can Detect AF, Influence Care: eBRAVE-AF

News Conference News ESC 2022

Smartphone App Can Detect AF, Influence Care: eBRAVE-AF

August 30, 2022

CMR, PET Similar for Identifying Coronary Disease After CTA: Dan-NICAD 2

News Conference News ESC 2022

CMR, PET Similar for Identifying Coronary Disease After CTA: Dan-NICAD 2

August 29, 2022

‘Hot’ Plaque on Noninvasive PET May Presage MI, CV Death: PRE18FFIR

News Conference News ESC 2022

‘Hot’ Plaque on Noninvasive PET May Presage MI, CV Death: PRE18FFIR

August 28, 2022

No Hints of Cognitive Defects With ARNIs in HFpEF

News Conference News ESC 2022

No Hints of Cognitive Defects With ARNIs in HFpEF: PERSPECTIVE

August 26, 2022

TIME of Antihypertensive Dose Doesn’t Matter for CV Protection Open With no difference between nighttime and morning dosing, “patients can take their tablets whenever it’s convenient.” configuration options With no difference between nighttime and morning dosing, “patients can take their tablets whenever it’s convenient.”

News Conference News ESC 2022

TIME of Antihypertensive Dose Doesn’t Matter for CV Protection

August 26, 2022

Less Paravalvular Leak With Newer Acurate neo2 TAVI: Registry

News Conference News TVT 2022

Less Paravalvular Leak With Newer Acurate neo2 TAVI: Registry

Michael O'Riordan

June 13, 2022

Aficamten Safe, Effective for Up to 6 months in Obstructive HCM: REDWOOD-HCM OLE

News Conference News ESC Heart Failure 2022

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

May 31, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.